How Does RESTASIS® Ophthalmic Emulsion Differ
From Artificial Tears?
Artificial tears can provide temporary relief by putting water and lubricants on the surface of the eye. However, artificial tears cannot increase tear production.
| RESTASIS® | Artificial Tears |
|---|---|
| Increases tear production in patients with a certain type of Chronic Dry Eye1,2 | Provide temporary symptomatic relief |
| FDA-approved Rx therapy1 | OTC remedy |
| BID Rx therapy1 | May need to be applied several times throughout the day |
| Presumed to treat underlying cause1,2 | Provide palliative relief of symptoms |
| Significant improvement at 1 month with continued improvement at 3 and 6 months1-3 |
Provide symptomatic relief but do not increase tear production |
References
- RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% [prescribing information]. Irvine, Calif: Allergan, Inc; 2003.
- Sall K, Stevenson OD, Mundorf TK, Reis BL, and the CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000:107:631-639.
- Data on file. Allergan, Inc.
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.